Capital Investment Counsel Inc Cuts Stake in Pfizer Inc. (NYSE:PFE)

Capital Investment Counsel Inc reduced its stake in Pfizer Inc. (NYSE:PFE) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 59,517 shares of the biopharmaceutical company’s stock after selling 3,963 shares during the period. Capital Investment Counsel Inc’s holdings in Pfizer were worth $1,713,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer during the third quarter valued at $30,000. GoalVest Advisory LLC boosted its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer during the third quarter valued at $34,000. VisionPoint Advisory Group LLC boosted its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer during the fourth quarter valued at $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Trading Up 1.2 %

PFE traded up $0.31 during trading hours on Monday, reaching $25.71. 5,266,429 shares of the company’s stock traded hands, compared to its average volume of 41,549,098. The firm has a 50-day moving average price of $26.96 and a 200 day moving average price of $28.36. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $145.58 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.53%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.